| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ROVI Overview
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €60.00 |
| 52 Week High | €30.20 |
| 52 Week Low | €68.80 |
| Beta | 0.62 |
| 1 Month Change | 6.01% |
| 3 Month Change | -1.96% |
| 1 Year Change | 92.93% |
| 3 Year Change | 270.37% |
| 5 Year Change | 385.83% |
| Change since IPO | 500.00% |
Recent News & Updates
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Shareholder Returns
| ROVI | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 6.6% | 1.4% | -0.6% |
| 1Y | 92.9% | 18.9% | 23.8% |
Return vs Industry: ROVI exceeded the Spanish Pharmaceuticals industry which returned 18.9% over the past year.
Return vs Market: ROVI exceeded the Spanish Market which returned 23.8% over the past year.
Price Volatility
| ROVI volatility | |
|---|---|
| ROVI Beta | 0.62 |
| Industry Beta | 0.44 |
| Market Beta | 1 |
Stable Share Price: ROVI is more volatile than 90% of Spanish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ROVI's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,499 | Juan Lopez-Belmonte Encina | https://www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.
Laboratorios Farmaceuticos Rovi Fundamentals Summary
| ROVI fundamental statistics | |
|---|---|
| Market Cap | €3.36b |
| Earnings (TTM) | €82.49m |
| Revenue (TTM) | €518.88m |
40.8x
P/E Ratio6.5x
P/S RatioIs ROVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROVI income statement (TTM) | |
|---|---|
| Revenue | €518.88m |
| Cost of Revenue | €239.72m |
| Gross Profit | €279.16m |
| Expenses | €196.68m |
| Earnings | €82.49m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.47 |
| Gross Margin | 53.80% |
| Net Profit Margin | 15.90% |
| Debt/Equity Ratio | 13.8% |
How did ROVI perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield26%
Payout RatioValuation
Is Laboratorios Farmaceuticos Rovi undervalued compared to its fair value and its price relative to the market?
1.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ROVI (€60) is trading below our estimate of fair value (€60.82)
Significantly Below Fair Value: ROVI is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ROVI is poor value based on its PE Ratio (40.8x) compared to the European Pharmaceuticals industry average (27.7x).
PE vs Market: ROVI is poor value based on its PE Ratio (40.8x) compared to the Spanish market (23.2x).
Price to Earnings Growth Ratio
PEG Ratio: ROVI is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: ROVI is overvalued based on its PB Ratio (8.3x) compared to the XE Pharmaceuticals industry average (3.4x).
Future Growth
How is Laboratorios Farmaceuticos Rovi forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
18.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROVI's forecast earnings growth (18.5% per year) is above the savings rate (0.9%).
Earnings vs Market: ROVI's earnings (18.5% per year) are forecast to grow faster than the Spanish market (16.8% per year).
High Growth Earnings: ROVI's earnings are forecast to grow, but not significantly.
Revenue vs Market: ROVI's revenue (8.4% per year) is forecast to grow faster than the Spanish market (6.5% per year).
High Growth Revenue: ROVI's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROVI's Return on Equity is forecast to be high in 3 years time (23.8%)
Past Performance
How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?
30.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROVI has high quality earnings.
Growing Profit Margin: ROVI's current net profit margins (15.9%) are higher than last year (13.3%).
Past Earnings Growth Analysis
Earnings Trend: ROVI's earnings have grown significantly by 30.4% per year over the past 5 years.
Accelerating Growth: ROVI's earnings growth over the past year (56.5%) exceeds its 5-year average (30.4% per year).
Earnings vs Industry: ROVI earnings growth over the past year (56.5%) exceeded the Pharmaceuticals industry 10.2%.
Return on Equity
High ROE: ROVI's Return on Equity (20.4%) is considered high.
Financial Health
How is Laboratorios Farmaceuticos Rovi's financial position?
Financial Position Analysis
Short Term Liabilities: ROVI's short term assets (€439.3M) exceed its short term liabilities (€167.4M).
Long Term Liabilities: ROVI's short term assets (€439.3M) exceed its long term liabilities (€73.0M).
Debt to Equity History and Analysis
Debt Level: ROVI's debt to equity ratio (13.8%) is considered satisfactory.
Reducing Debt: ROVI's debt to equity ratio has reduced from 22.6% to 13.8% over the past 5 years.
Debt Coverage: ROVI's debt is well covered by operating cash flow (267.7%).
Interest Coverage: ROVI's interest payments on its debt are well covered by EBIT (309.7x coverage).
Balance Sheet
Dividend
What is Laboratorios Farmaceuticos Rovi current dividend yield, its reliability and sustainability?
0.63%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ROVI's dividend (0.64%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (1.5%).
High Dividend: ROVI's dividend (0.64%) is low compared to the top 25% of dividend payers in the Spanish market (5.45%).
Stability and Growth of Payments
Stable Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.
Growing Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ROVI is not paying a notable dividend for the Spanish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ROVI's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
12.1yrs
Average management tenure
CEO
Juan Lopez-Belmonte Encina
4.75yrs
Tenure
€561,000
Compensation
Mr. Juan Lopez-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. He has been with Laboratorios Farmaceuticos ROVI since 1994 and served as its Ge...
CEO Compensation Analysis
Compensation vs Market: Juan's total compensation ($USD652.55K) is below average for companies of similar size in the Spanish market ($USD1.46M).
Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: ROVI's management team is seasoned and experienced (12.1 years average tenure).
Board Members
Experienced Board: ROVI's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Laboratorios Farmaceuticos Rovi, S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: Laboratorios Farmaceuticos Rovi, S.A.
- Ticker: ROVI
- Exchange: BME
- Founded: 1946
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €3.364b
- Shares outstanding: 56.07m
- Website: https://www.rovi.es
Number of Employees
Location
- Laboratorios Farmaceuticos Rovi, S.A.
- Calle José Isbert, 2
- Pozuelo de Alarcón
- Madrid
- Madrid
- 28223
- Spain
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/24 17:55 |
| End of Day Share Price | 2021/10/22 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.